The Influence of Intervening on the Pharmaceutical Consultation Targeting Outpatients with Advanced Non-small Cell Lung Cancer Receiving Erlotinib Treatment-Reference-Cited by-同舟云学术

The Influence of Intervening on the Pharmaceutical Consultation Targeting Outpatients with Advanced Non-small Cell Lung Cancer Receiving Erlotinib Treatment

Published:2021-09-01 Issue:9 Volume:44 Page:1280-1285
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Nishibe-Toyosato Seira¹,Ando Yosuke¹,Goto Yasuhiro²,Hayashi Takahiro³,Ito Kaori⁴,Matsuda Hidezo¹,Tsujii Naho¹,Tsuge Masahiro¹,Kawada Kenji⁵,Imaizumi Kazuyoshi²,Yamada Shigeki¹

Affiliation:

1. Department of Clinical Pharmacy, Fujita Health University School of Medicine

2. Department of Respiratory Medicine, Fujita Health University School of Medicine

3. College of Pharmacy, Kinjo Gakuin University

4. Department of Hematology, Fujita Health University School of Medicine

5. Department of Medical Oncology, Fujita Health University School of Medicine

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/44/9/44_b21-00167/_pdf

Reference20 articles.

1. 1) Uramoto H, Kagami S, Iwashige A, Tsukada J. Evaluation of the quality of life between inpatients and outpatients receiving cancer chemotherapy in Japan. Anticancer Res., 27, 1127–1132 (2007).

2. 2) Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Int. J. Clin. Oncol., 22, 70–78 (2017).

3. 3) Kobayashi Y, Komatsu Y, Yuki S, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol., 11, 617–627 (2015).

4. 4) Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, Horai T, Masuda N, Eguchi K, Mitsudomi T, Yokota S, Segawa Y, Ichinose Y, Fukuoka M, Saijo N. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res., 30, 557–563 (2010).

5. 5) Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol., 23, 5235–5246 (2005).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacist–Urologist Collaborative Management for Patients with Renal Cell Carcinoma Receiving Pazopanib Monotherapy;Biological and Pharmaceutical Bulletin;2023-08-01